AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28239805
Drug: Continuous pump
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous pump injection
Trial: 15545949
Drug: Fluticasone/Salmeterol (FP/S)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone/Salmeterol (FP/S) combination
Trial: 15545949
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with a free combination of an inhaled corticosteroid and a long-acting beta2-agonist (TA)
Trial: 9731837
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg prostaglandin E2 intracervical gel (Prepidil) every 6 hours for 2 doses
Trial: 9731837
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg prostaglandin E2 slow release vaginal pessary (Cervidil)
Trial: 7984606
Drug: Ultrahigh-frequency electromagnetic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrahigh-frequency electromagnetic radiation (UHF) therapy combined with specific chemicals, 10 sessions using a YAVOR device at 6.4 and 7.1 mm.
Trial: 7984606
Drug: Ultrahigh-frequency electromagnetic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrahigh-frequency electromagnetic radiation (UHF) therapy combined with specific chemicals.
Trial: 7984606
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (drug therapy alone).
Trial: 2722718
Drug: Latamoxef 2
RxNorm normalized name: latamoxef
DrugBank: Latamoxef (DB04570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Latamoxef 2 g
Trial: 2291659
Drug: Cefmetazole 2
RxNorm normalized name: cefmetazole 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefmetazole 2 g
Trial: 798282
Drug: Cyclic chemotherapy
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic chemotherapy with Arabinosyl Cytosine (ARA C), Vincristine, and Prednisone
Trial: 28132007
Drug: ibobbly app
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ibobbly app (acceptance‐based therapy) over 6 weeks
Trial: 14963464
Drug: sildenafil 50
RxNorm normalized name: sildenafil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sildenafil 50 mg
Trial: 8971288
Drug: Effervescent ranitidine
RxNorm normalized name: ranitidine Effervescent Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effervescent ranitidine 150 mg
Trial: 8971288
Drug: Effervescent ranitidine
RxNorm normalized name: ranitidine Effervescent Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effervescent ranitidine 300 mg
Trial: 8971288
Drug: Standard ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ranitidine 150 mg
Trial: 8971288
Drug: Standard ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ranitidine 300 mg
Trial: 6360571
Drug: Control night
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control night (no CPAP treatment).
Trial: 28744557
Drug: Active pulsed
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active pulsed magnetic stimulation (PMS) for 8 weeks (twice/week)
Trial: 28744557
Drug: Sham pulsed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham pulsed magnetic stimulation for 8 weeks (twice/week)
Trial: 25079861
Drug: Colestilan 3
RxNorm normalized name: colestilan
DrugBank: Colestilan chloride (DB11634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colestilan 3 - 12 g/day
Trial: 25079861
Drug: Simvastatin 10
RxNorm normalized name: simvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 10 - 40 mg/day
Trial: 15863540
Drug: Preoperative vaginal
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative vaginal preparation with povidone-iodine
Trial: 11967501
Drug: Isosorbide 5‐mononitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide 5‐mononitrate 40 mg 4 hours or 10 hours before the operation
Trial: 8275477
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no preoperative treatment)
Trial: 11967501
Drug: Isosorbide 5‐mononitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide 5‐mononitrate 40 mg
Trial: 2757664
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid sustained release formulation (Contrheuma retard) 300 mg initial dose and 350 mg retard formulation
Trial: 2757664
Drug: Standard ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ASA solution for intravenous administration
Trial: 2757664
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid sustained release formulation (Contrheuma retard)
Trial: 337694
Drug: Novocain treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novocain treatment (2% procain 5ml, intramuscular injections, 3 times a week, 12 injections a month)
Trial: 337694
Drug: Gerovital H3
RxNorm normalized name: Vitamin H3
DrugBank: Procaine (DB00721)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gerovital H3 treatment according to A. Aslan's method
Trial: 30755016
Drug: Exercise non-responders
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise non-responders (defined as change in peak oxygen uptake <1 ml/kg/min)
Trial: 26770664
Drug: D-cycloserine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-cycloserine (50 mg) given 30 minutes prior to weekly group social skills training for 10 weeks
Trial: 26770664
Drug: Placebo given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given 30 minutes prior to weekly group social skills training for 10 weeks
Trial: 25132784
Drug: 4-L sulfa-free
RxNorm normalized name: 2-Sulfa-4-methylpyrimidine
DrugBank: Sulfamerazine (DB01581)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-L sulfa-free polyethylene glycol (4-L SF-PEG)
Trial: 25132784
Drug: 2-L polyethylene
RxNorm normalized name: Iron(2+) L-ascorbate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-L polyethylene glycol solution with ascorbic acid (2-L PEG + Asc)
Trial: 22556186
Drug: Personal health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personal health record (PHR)‐linked medications module
Trial: 19173689
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate 50 mg
Trial: 17253995
Drug: Partial body-weight-supported
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial body-weight-supported treadmill training (PBWSTT), conducted twice a week for 6 weeks
Trial: 16022849
Drug: Mifepristone 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 10 mg (3 courses) with condoms
Trial: 9832286
Drug: Cefepime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime (2 g intravenously every 12 h)
Trial: 7858479
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplementation (10 mg/day)
Trial: 2627107
Drug: Alpress osmotic
RxNorm normalized name: Ez2go Osmotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpress osmotic tablet (prazosin)
Trial: 825744
Drug: Calcium in
RxNorm normalized name: Avail Calcium Intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium in combination with vitamin D2 (calciferol), given orally
Trial: 25645164
Drug: Parent-augmented One-Session
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-augmented One-Session Treatment (A-OST)
Trial: 25645164
Drug: Child-focused One-Session
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child-focused One-Session Treatment (OST)
Trial: 24423417
Drug: 68.8 mg
RxNorm normalized name: glycerin 68.8 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 68.8 mg lidocaine with 50 μg epinephrine plus 0.9 M mannitol (5 mL formulation)
Trial: 24423417
Drug: 68.8 mg
RxNorm normalized name: glycerin 68.8 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 68.8 mg lidocaine with 50 μg epinephrine (1.72 mL formulation)
Trial: 22233822
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (MC) at 10 or 20 mg/m² every 3 weeks
Trial: 15586886
Drug: G0-micronucleus (MN)
RxNorm normalized name: Mn 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G0-micronucleus (MN) assay with low dose-rate (LDR) irradiation (4 mGy/min)
Trial: 15586886
Drug: G0-micronucleus (MN)
RxNorm normalized name: Mn 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G0-micronucleus (MN) assay with high dose-rate (HDR) irradiation (1 Gy/min)
Trial: 15586886
Drug: Dose-rate sparing
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-rate sparing index
Trial: 1489037
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg diclofenac (intramuscular)
Trial: 3930688
Drug: Liposyn at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposyn at 0.34 g
Trial: 3930688
Drug: Liposyn at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposyn at 0.68 g
Trial: 3930688
Drug: Modified Liposyn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Liposyn at 0.68 g/kg/day
Trial: 3930688
Drug: Reference group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference group (fat-free parenteral nutrition)
Trial: 25884981
Drug: Medium dose:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose: 50 mg Zn, 75 mcg Se, 250 IU vitamin E
Trial: 25884981
Drug: Low dose:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose: 25 mg Zn, 50 mcg Se, 250 IU vitamin E
Trial: 25884981
Drug: Standard supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard supplement (control)
Trial: 22080020
Drug: 150 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/kg PFA
Trial: 22080020
Drug: 750 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg/kg PFA
Trial: 22080020
Drug: 1,500 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,500 mg/kg PFA
Trial: 10680104
Drug: Thiopental 2.5
RxNorm normalized name: thiopental 2.5 g intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental 2.5 +/- 1.0 mg/kg
Trial: 10680104
Drug: Propofol 1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1.6 +/- 0.6 mg/kg
Trial: 1712323
Drug: Mifepristone, 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone, 25 mg five times at 12-hour intervals (n = 192)
Trial: 1712323
Drug: Mifepristone, 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone, 600 mg as a single dose (n = 193)
Trial: 6179101
Drug: Indobufen (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indobufen (100 mg i.v.)
Trial: 27513257
Drug: Lidocaine with
RxNorm normalized name: Lidocaine with Tegaderm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine with epinephrine (Group L)
Trial: 27513257
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline solution with epinephrine (Group S)
Trial: 25167690
Drug: Micronutrient supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient supplementation (MMS) 'Sprinkles' (powdered formulation of iron, vitamins A and C, folic acid, and zinc)
Trial: 20642549
Drug: Ticagrelor 100
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 100 mg twice daily
Trial: 20642549
Drug: Ticagrelor 300
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 300 mg once daily
Trial: 20642549
Drug: Ticagrelor 50-600
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 50-600 mg once daily
Trial: 18095612
Drug: Domestic Acarbose
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Domestic Acarbose capsule (DAC)
Trial: 15735805
Drug: Triple antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antiplatelet therapy (Aspirin, Clopidogrel, Dipyridamole - ACD)
Trial: 15735805
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Aspirin and Clopidogrel (AC)
Trial: 15735805
Drug: Aspirin, Clopidogrel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, Clopidogrel, Dipyridamole (ACD)
Trial: 9851729
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous immunoglobulin (IVIg) in patients with DM
Trial: 9851729
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous immunoglobulin (IVIg) in patients with IBM
Trial: 9851729
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous immunoglobulin (IVIg) in specific muscle groups in IBM patients
Trial: 9851729
Drug: Conventional therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapies in patients with DM
Trial: 2050832
Drug: Hydrochlorothiazide (HC)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HC) 72 +/- 26 mg/d
Trial: 2050832
Drug: Spironolactone (SP)
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone (SP) 144 +/- 53 mg/d
Trial: 6846677
Drug: Intensive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive group treatment procedures
Trial: 30001258
Drug: High-dose folic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose folic acid (5 mg/wk)
Trial: 30001258
Drug: Low-dose folic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose folic acid (0.8 mg/wk)
Trial: 29482433
Drug: Dengvaxia (tetravalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dengvaxia (tetravalent live-attenuated 3-dose vaccine composed of chimeras of yellow fever 17D and the four dengue viruses)
Trial: 24998405
Drug: Conservative management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative management without physical therapy
Trial: 21623342
Drug: Demand-only PCEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demand-only PCEA (0.125% levobupivacaine plus 1.5 mcg/mL fentanyl, 10 mL bolus with a 20 min lock time)
Trial: 21623342
Drug: PCEA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA plus background infusion (10 mL/h)
Trial: 19874650
Drug: 1.6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6 mg/kg oral MDMA
Trial: 19874650
Drug: 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg oral MDMA
Trial: 17032096
Drug: Forgiveness Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forgiveness Therapy (FT)
Trial: 17032096
Drug: Alternative Treatment
RxNorm normalized name: HERBS/ALTERNATIVE THERAPIES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative Treatment (AT)
Trial: 15068419
Drug: L. brevis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. brevis (CD2)
Trial: 10647315
Drug: L‐NMMA (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NMMA (6 mg/kg intravenous infusion)
Trial: 15871635
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir (1000 mg three times daily)
Trial: 1610712
Drug: 1% crude
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% crude coal tar used twice daily for 10 days
Trial: 6705284
Drug: Oral prenalterol
RxNorm normalized name: prenalterol
DrugBank: Prenalterol (DB13777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prenalterol at doses of 20, 40, 100, and 200 mg daily for four weeks
Trial: 6705284
Drug: Oral prenalterol
RxNorm normalized name: prenalterol
DrugBank: Prenalterol (DB13777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prenalterol
Trial: 30016948
Drug: Preventive Physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive Physical Therapy (PPT)
Trial: 23998969
Drug: OM3‐FFA 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OM3‐FFA 2 g/d
Trial: 24528690
Drug: OM3‐FFA 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OM3‐FFA 3 g/d
Trial: 23998969
Drug: OM3‐FFA 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OM3‐FFA 4 g/d
Trial: 23998969
Drug: Control (olive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (olive oil [OO] 4 g/d)
Trial: 23171601
Drug: Worry intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Worry intervention (cognitive-behavioral treatment)
Trial: 26537725
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (treatment as usual)
Trial: 10207545
Drug: Zidovudine (ZDV)
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine (ZDV) monotherapy and combination arms
Trial: 10445104
Drug: Gonadotropins (GN)
RxNorm normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropins (GN) combined with growth hormone (GH) for 6 months
Trial: 2142930
Drug: Gestodene-containing formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gestodene-containing formulation
Trial: 2142930
Drug: Desogestrel-containing formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desogestrel-containing formulation
Trial: 902005
Drug: Counselling on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counselling on medication errors
Trial: 902005
Drug: Tear-off daily
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tear-off daily calendar
Trial: 902005
Drug: Pill wheel
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pill wheel
Trial: 30862265
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (EVT) for transferred patients
Trial: 26458813
Drug: Titanium Grade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titanium Grade IV (Ti Grade IV) implants
Trial: 23992793
Drug: General therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General therapy skills (feedback and understanding)
Trial: 21574351
Drug: Vacuum-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vacuum-assisted therapy (V.A.C. Therapy system)
Trial: 21574351
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (including debridement)
Trial: 19121493
Drug: Sandblasting +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandblasting + silane-coupling agent (Group 2)
Trial: 19121493
Drug: Tribochemical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tribochemical treatment (Group 3)
Trial: 16713778
Drug: Midazolam (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (7 mg)
Trial: 16713778
Drug: Etomidate (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate (20 mg)
Trial: 11312014
Drug: Monovalent dengue
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent dengue vaccines (dengue-1, dengue-2, dengue-3, dengue-4)
Trial: 11312014
Drug: Vaccine vehicle
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine vehicle (control)
Trial: 11312014
Drug: All dengue-3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All dengue-3, dengue-4, and tetravalent vaccine recipients
Trial: 11312014
Drug: Dengue-1 and
RxNorm normalized name: dengue virus live antigen, CYD serotype 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dengue-1 and dengue-2 vaccine recipients
Trial: 11312014
Drug: Dengue-2, dengue-3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dengue-2, dengue-3, dengue-4, and 60% of dengue-1 vaccine recipients
Trial: 11312014
Drug: Tetravalent vaccine
RxNorm normalized name: DENGUE TETRAVALENT VACCINE,LIVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent vaccine recipients
Trial: 9250115
Drug: Oat-bran test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat-bran test meal (16.3 g fiber)